We are aware of over 70 publications that have sought to relate TP53 mutation with clinical outcome in ovarian cancer, with conflicting conclusions about the importance of TP53 mutations for tumour aggressiveness, response to treatment, and survival. The gene discussed is TP53; the disease is ovarian cancer.